Polypharmacy in patients with multiple sclerosis: a gender-specific analysis.
Comorbidity
Concomitant drugs
Gender
Medication management
Multiple sclerosis
Patient care
Polypharmacy
Journal
Biology of sex differences
ISSN: 2042-6410
Titre abrégé: Biol Sex Differ
Pays: England
ID NLM: 101548963
Informations de publication
Date de publication:
27 05 2019
27 05 2019
Historique:
received:
25
03
2019
accepted:
17
05
2019
entrez:
29
5
2019
pubmed:
28
5
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Multiple sclerosis (MS) affects about three times more women than men. Due to variable MS courses, multiple therapies are necessary in clinical practice. We aimed at conducting sex-specific analyses of MS patients regarding polypharmacy (≥ 5 drugs) and at identifying differences in the medication spectrum. Clinico-demographic data were gathered from 306 patients using clinical examinations, structured patient interviews, and patient records. Statistical data analyses were performed to evaluate whether the same or different factors are associated with polypharmacy in both genders. Women (N = 218) and men (N = 88) showed similar polypharmacy rates (56.0% vs. 58.0%; p = 0.799). For both genders, higher age, severe disability degrees, comorbidities, and inpatient treatment were significantly associated with a higher polypharmacy risk. Low educational levels were predictors of polypharmacy only in women. Fampridine (p < 0.021) and antispasmodics (p < 0.010) were used more often by men, while women took more frequently thyroid medications (p < 0.001) and contraceptives (p < 0.001). The age-related increase in medication use was much stronger in women (p < 0.001). Male and female MS patients with older age, comorbidities, higher disability degree, and inpatient treatment are at greater risk of polypharmacy. Future studies should examine the occurrence of clinically relevant drug interactions in MS patients stratified by sex.
Sections du résumé
BACKGROUND
Multiple sclerosis (MS) affects about three times more women than men. Due to variable MS courses, multiple therapies are necessary in clinical practice.
OBJECTIVE
We aimed at conducting sex-specific analyses of MS patients regarding polypharmacy (≥ 5 drugs) and at identifying differences in the medication spectrum.
METHODS
Clinico-demographic data were gathered from 306 patients using clinical examinations, structured patient interviews, and patient records. Statistical data analyses were performed to evaluate whether the same or different factors are associated with polypharmacy in both genders.
RESULTS
Women (N = 218) and men (N = 88) showed similar polypharmacy rates (56.0% vs. 58.0%; p = 0.799). For both genders, higher age, severe disability degrees, comorbidities, and inpatient treatment were significantly associated with a higher polypharmacy risk. Low educational levels were predictors of polypharmacy only in women. Fampridine (p < 0.021) and antispasmodics (p < 0.010) were used more often by men, while women took more frequently thyroid medications (p < 0.001) and contraceptives (p < 0.001). The age-related increase in medication use was much stronger in women (p < 0.001).
CONCLUSION
Male and female MS patients with older age, comorbidities, higher disability degree, and inpatient treatment are at greater risk of polypharmacy. Future studies should examine the occurrence of clinically relevant drug interactions in MS patients stratified by sex.
Identifiants
pubmed: 31133051
doi: 10.1186/s13293-019-0243-9
pii: 10.1186/s13293-019-0243-9
pmc: PMC6537438
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Références
Neurology. 2017 Nov 28;89(22):2222-2229
pubmed: 29093064
Mult Scler. 2015 Mar;21(3):282-93
pubmed: 25533299
Clin Rehabil. 2007 Sep;21(9):771-81
pubmed: 17875557
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Acta Clin Belg. 2016 Jun;71(3):158-66
pubmed: 27105401
J Clin Endocrinol Metab. 2014 Mar;99(3):923-31
pubmed: 24423323
Proc Nutr Soc. 2019 Feb;78(1):97-109
pubmed: 30375305
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
Geriatr Gerontol Int. 2015 Feb;15(2):141-6
pubmed: 24467719
J Biomed Inform. 2012 Feb;45(1):184-98
pubmed: 21925288
Am J Phys Med Rehabil. 2010 Jun;89(6):446-57
pubmed: 20216060
Expert Opin Drug Saf. 2014 Jan;13(1):57-65
pubmed: 24073682
Sci Data. 2017 Oct 31;4:170167
pubmed: 29087369
Adv Ther. 2016 May;33(5):834-47
pubmed: 27090116
Mult Scler. 2011 Apr;17(4):468-77
pubmed: 21148266
Curr Neurol Neurosci Rep. 2018 May 23;18(7):36
pubmed: 29789964
Neurology. 2016 Apr 12;86(15):1446-1453
pubmed: 26865523
Handb Exp Pharmacol. 2012;(214):361-86
pubmed: 23027459
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Clin Interv Aging. 2013;8:1585-90
pubmed: 24348028
Neurotherapeutics. 2017 Oct;14(4):974-984
pubmed: 28766273
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
JAMA Neurol. 2018 Aug 1;75(8):1013-1021
pubmed: 29710293
Int J Clin Pharm. 2013 Dec;35(6):1229-35
pubmed: 24104761
J Psychosom Res. 2014 May;76(5):400-4
pubmed: 24745782
Arch Public Health. 2015 Nov 09;73:50
pubmed: 26557365
Neurol Res. 2015 Aug;37(8):662-73
pubmed: 25905471
Expert Rev Neurother. 2010 Sep;10(9):1383-90
pubmed: 20819010
Int J Neurosci. 2013 Jun;123(6):400-8
pubmed: 23297730
Braz J Med Biol Res. 2015 Aug;48(8):751-8
pubmed: 26108100
BMC Med. 2015 Apr 07;13:74
pubmed: 25889849
Nutr J. 2014 Feb 06;13:14
pubmed: 24499096
Br J Clin Pharmacol. 2015 Oct;80(4):796-807
pubmed: 25619317
J Am Geriatr Soc. 2009 Jan;57(1):62-9
pubmed: 19054196
J Investig Med. 2017 Jun;65(5):883-891
pubmed: 28130412
Complement Ther Med. 2014 Feb;22(1):166-72
pubmed: 24559832
Eur J Phys Rehabil Med. 2015 Apr;51(2):207-10
pubmed: 25180640
Expert Rev Neurother. 2014 Sep;14(9):1029-42
pubmed: 25109614
J Womens Health (Larchmt). 2014 Feb;23(2):112-9
pubmed: 24206025
Oman Med J. 2016 Nov;31(6):421-425
pubmed: 27974957
Expert Rev Clin Immunol. 2018 Feb;14(2):137-153
pubmed: 29318902
JAMA. 2016 Oct 11;316(14):1464-1474
pubmed: 27727382
Mult Scler Int. 2015;2015:317859
pubmed: 26221541